USFDA accepts sBLA of TIVDAK for priority review for patients with metastatic cervical cancer
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The deal includes upfront payments, milestone payments and ongoing royalties
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Demonstrate significant bleed reduction in hemophilia A and B
Subscribe To Our Newsletter & Stay Updated